LB Pharmaceuticals completed a private placement raising $150 million in July 2026, with net proceeds of approximately $140.9 million to fund the expansion of its lead asset LB-102 into new indications and for general corporate purposes. The company reported financial results for the quarter ended September 30, 2026, showing a net loss of $59.1 million compared to $3.6 million in the prior year period, driven by increased research and development expenses related to Phase 3 trials. Cash, cash equivalents, and short-term investments stood at $403.8 million as of September 30, 2026, providing a runway beyond Q2 2029. The company also appointed Susan G. Kozauer as Chief Medical Officer and Joseph Miller as Chief Financial Officer. LB Pharmaceuticals is a neuromedicines company developing therapies for underserved brain disorders.
